Abstract: A spheroid tissue microarray comprises an array of tissue spheroids embedded within a porous mold. The product may be impregnated with a wax or resin and sectioned, and contains spheroids which are precisely located in a regular geometric grid. A method of manufacturing a spheroid tissue microarray comprises the steps of: forming a mold of porous material from liquid mold material in a casting mold, and allowing the liquid mold material to set; removing the porous mold from the casting mold; topping up the porous mold with further liquid mold material, and allowing recesses to form in the surface of the mold by the drawing-in of liquid mold material through shrinkage as the liquid mold material sets; placing tissue spheroids into the recesses in the surface of the porous mold; and sealing the tissue spheroids within the mold by topping off with liquid mold material and allowing the liquid mold material to set.
Abstract: The invention provides devices for supporting regeneration of body tissue and of tubular structures, such as the esophagus or intestine, and methods for making and for using the devices.
Type:
Grant
Filed:
September 30, 2016
Date of Patent:
April 26, 2022
Assignees:
The Administrators of the Tulane Educational Fund, Nanofiber Solutions, LLC
Inventors:
Derek C. Dashti, Aline M. Betancourt, Jed Johnson, Ruth Waterman
Abstract: The invention provides a method of producing human immature dental pulp stem cells (hIDPSCs) expressing CD44 and CD13 and lacking expression of CD146. The invention also provides compositions for use in the treatment of a neurological disease or condition selected from the group consisting of Parkinson's disease (PD), multiple sclerosis, amyotrophic lateral sclerosis (ALS), stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease, Huntington's disease (HD), autism, schizophrenia, stroke, ischemia, a motor disorder, and a convulsive disorder.
Type:
Grant
Filed:
September 8, 2018
Date of Patent:
April 19, 2022
Assignees:
AVITA INTERNATIONAL LTD., FUNDAÇÃO BUTANTAN
Abstract: Particles are released from a particle-containing area of a first surface of a porous matrix. The particle-containing area is contacted with a liquid medium and sonic energy is applied to an opposing area on a second surface of the porous matrix, wherein the opposing area is opposite to the particle-containing area. The particles may be biological particles or non-biological particles.
Abstract: The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs wherein the hIDPSCs express CD44 and CD13. For example, for treating neurological diseases or conditions including supporting the neuro-protective mechanism in subjects diagnosed with early HD or repairing lost DA neurons in subjects diagnosed with PD.
Type:
Grant
Filed:
September 8, 2018
Date of Patent:
March 22, 2022
Assignees:
AVITA INTERNATIONAL LTD., FUNDAÇÂO BUTANTAN
Abstract: The disclosure provides a method of using blood or fractions thereof, e.g., serum, obtained from a mammal subjected to liver surgery, for example, obtained following a partial hepatectomy, to increase the engraftment, proliferation and/or functionality of cells on a biocompatible scaffold.
Type:
Grant
Filed:
September 6, 2017
Date of Patent:
March 22, 2022
Assignees:
Mayo Foundation for Medical Education and Research, Miromatrix Medical Inc.
Inventors:
Jeffrey Ross, Anne Young, Allie Haarstad, Scott Nyberg
Abstract: A bacteriophage structure, a method of making the structure, and uses of the structure are described. The structure is a substrate with a surface having an ordered arrangement of parallel microridges thereon. Each microridge is composed of a plurality of nanoridges and has a longitudinal axis. Each nanoridge contains a bundle of phage nano fibers having longitudinal axes. The phage nanofibers in each nanoridge bundle are arranged in a substantially smectic alignment. The longitudinal axis of each microridge is perpendicular to the longitudinal axes of the phage nanofibers which make up the nanoridges of the microridge. The structure may be used as a growth surface for inducing differentiation of stem cells such as neural progenitor cells.
Type:
Grant
Filed:
April 10, 2020
Date of Patent:
March 1, 2022
Assignee:
The Board of Regents of the University of Oklahoma
Abstract: Fibrous structures containing a surface care composition, and more particularly dry fibrous structures containing a surface care composition comprising one or more bacteriophage, methods of making same, and methods for treating surfaces using same are provided.
Type:
Grant
Filed:
January 22, 2015
Date of Patent:
February 22, 2022
Assignee:
The Procter & Gamble Company
Inventors:
Paul Thomas Weisman, Duane Larry Charbonneau, Serena Rae Heyse
Abstract: Provided herein are soluble soft tissue protein compositions that can contain one or more soft-tissue bioactive factors, methods of making the soluble soft tissue protein compositions, and methods of using the soluble soft tissue protein compositions.
Type:
Grant
Filed:
October 12, 2016
Date of Patent:
February 22, 2022
Assignee:
Biologies Technologies
Inventors:
Amit Prakash Govil, Bryan Choi, Sahil Jalota
Abstract: In one aspect, the disclosure provides a method of defining a Raman signature of a culture component, the method comprising: obtaining a Raman spectrum of a culture component in a non-interfering or minimally-interfering solution, identifying peaks in the Raman spectrum that are associated with the culture component, obtaining a Raman spectrum of a culture medium comprising the culture component, and, removing peaks of the culture component in the Raman spectrum of the culture medium that are distorted compared to the peaks identified in the Raman spectrum of the culture component in a non-interfering or minimally-interfering solution.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
February 15, 2022
Assignee:
Biogen MA Inc.
Inventors:
Justin Moretto, Brandon Berry, Alex Doane
Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
Abstract: The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.
Type:
Grant
Filed:
January 16, 2018
Date of Patent:
January 4, 2022
Assignee:
Entegrion, Inc.
Inventors:
Thomas H. Fischer, Joseph A. DaCorta, Michael Lawrence Galiger
Abstract: The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs wherein the hIDPSCs express CD44 and CD13. For example, for treating neurological diseases or conditions including supporting the neuro-protective mechanism in subjects diagnosed with early HD or repairing lost DA neurons in subjects diagnosed with PD.
Type:
Grant
Filed:
March 9, 2016
Date of Patent:
December 28, 2021
Assignees:
AVITA INTERNATIONAL LTD., FUNDAÇÃO BUTANTAN
Abstract: The present invention discloses a composition and method of use for the general improvement of hypertension, high cholesterol, and cardiovascular health. The novel composition is comprised of thiamin (vitamin B1), vitamin B2 (as riboflavin-5?-phosphate), niacin (vitamin B3, as niacinamide), vitamin B6 (as pyridoxine hydrochloride), folic acid, vitamin C, vitamin D, calcium (as calcium carbonate), magnesium (as magnesium taurate), aged garlic extract, olive leaf extract (as 20% oleuropein), coenzyme Q10 (as ubiquinol), L-Arginine (as hydrochloride), L-Citrulline (as malate), and lycopene.
Abstract: Disclosed is a cell-derived extracellular matrix (ECM) derived in vitro from cells isolated from amniotic fluid, and methods of use for the isolation, maintenance, and proliferation of adherent cells including stem cells, as well as for the differentiation of stem cells.
Type:
Grant
Filed:
October 3, 2019
Date of Patent:
November 23, 2021
Assignee:
STEMBIOSYS, INC.
Inventors:
Travis Block, Edward S. Griffey, Mary Navarro
Abstract: This invention provides a nanoparticle made of: a potato protein; and a bioactive compound bound to the potato protein. The invention further provides foods or beverages, including clear ones, which are supplemented with the nanoparticles made of: a potato protein; and a hydrophobic bioactive compound bound to the potato protein. The process of making the nanoparticles of the invention, and methods for supplementing foods or beverages with hydrophobic bioactive compounds via the nanoparticles of the invention and are also provided.
Type:
Grant
Filed:
September 17, 2014
Date of Patent:
November 16, 2021
Assignee:
TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
Abstract: Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient.
Abstract: The present invention relates to a rotary rod for 3D bio-printing, in which the rotary rod is arranged horizontally and is driven to rotate, the rotary rod has a hollow structure and provided with at least one hole in a surface thereof, such that during a 3D bio-printing process, a nutrition solution passes through the hollow structure and a portion of the nutrition solution exudes via at least one hole. The present invention further provides a 3D bio-printing platform for supplying nutrition, comprising the rotary rod and a nutrition supply system, and a method of printing a tubular tissue using the bio-printing platform. The present invention, which reduces the possibility of resulting in tissue collapse from the effect of gravity, provides a new method of 3D bio-printing a tubular tissue and supplying nutrition in a printing process, with a wide application prospect.
Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
Abstract: Described herein is a novel, highly efficient system to remove erythrocytes and purify leukocytes would raise the quality of UCB and other transplant grafts, thereby significantly improving patient outcomes.
Type:
Grant
Filed:
November 16, 2015
Date of Patent:
October 12, 2021
Assignees:
University of Maryland, Baltimore, The Trustees of Princeton University
Inventors:
Curt I. Civin, James C. Sturm, Robert H. Austin